Drugs / Kanitinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02916095 | Nov 2016 → Jan 2020 | cancer | Beijing Konruns Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kanitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02916095 ↗ |
| Route | Oral | “Oral administration of Kanitinib tablets.” NCT02916095 ↗ |